rabeprazole has been researched along with Infections, Helicobacter in 289 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this multicenter, randomized, double-blind, double-dummy, positive-drug parallel-controlled, phase III study, Chinese patients with duodenal ulcers were randomized 1:1 to receive rabeprazole 10 mg + anaprazole placebo or rabeprazole placebo + anaprazole 20 mg once daily for 4 weeks." | 9.51 | Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study. ( Ding, J; Du, Y; Fan, H; Huang, C; Li, Z; Lyu, N; Pan, X; Pan, Z; Shi, Z; Sun, H; Wang, Q; Zhang, L; Zhu, H, 2022) |
| " Although there was no significant difference between placebo and rabeprazole groups in complete symptom relief for four major dyspeptic symptoms, the satisfactory symptom relief of rabeprazole 20 mg was significantly higher than placebo according to the dyspepsia symptom questionnaire (45." | 9.17 | Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. ( Arakawa, T; Fujimoto, K; Furuta, K; Furuta, T; Haruma, K; Higuchi, K; Hiraishi, H; Hongo, M; Inamori, M; Iwakiri, K; Iwakiri, R; Kanke, K; Kato, M; Kinoshita, Y; Kusano, M; Masuyama, H; Miwa, H; Nagahara, A; Naito, Y; Takahashi, S; Tominaga, K; Watanabe, S, 2013) |
| "Our study aimed to assess the effectiveness of esomeprazole or rabeprazole in combination with amoxicillin and clarithromycin for the eradication of Helicobacter pylori in Hong Kong non-ulcer dyspepsia (NUD) patients." | 9.14 | Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects. ( Chan, AK; Chan, FK; Chau, TS; Lee, KK; Lee, VW; Ling, TK; Waye, MM, 2010) |
| "To determine if the 4-week efficacy of rabeprazole 20 mg for resolving heartburn and regurgitation symptoms is non-inferior to esomeprazole 40 mg or 20 mg." | 9.14 | Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. ( Eggleston, A; Holtmann, G; Katelaris, PH; Nandurkar, S; Thorpe, P, 2009) |
| "To study the efficacy and safety of rabeprazole in peptic ulcer patients alone or combined with anti-Helicobacter pylori (Hp) agents." | 9.11 | [The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients]. ( Lin, SR, 2005) |
| "To investigate the effect of Helicobacter pylori eradication on endothelin-1 (ET-1) and nitric oxide (NO) in duodenal ulcer (DU) patients." | 9.11 | Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication. ( Chang, FY; Chen, CY; Lee, SD; Lu, CL; Lu, RH; Luo, JC, 2005) |
| " pylori infection on effectiveness of rabeprazole in primary and secondary care patients with gastro-oesophageal reflux disease." | 9.11 | Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? ( Bergmans, P; Boer, WA; Geldof, H; Hazelhoff, B; Smout, AJ; Tytgat, GN; Wit, NJ, 2004) |
| " pylori-positive patients with peptic ulcer disease were received rabeprazole 10 mg bid, amoxicillin 1,000 mg bid and clarithromycin 500 mg bid for a week." | 9.10 | [A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer]. ( Choi, BK; Chung, JM; Jang, YS; Lee, SH; Lee, YJ; Park, ET; Seol, SY; Yang, SY, 2003) |
| "It was to determine the efficacy of rabeprazole at 20 and 40 mg in addition to amoxicillin and clarithromycin in the treatment of active Helicobacter pylori-positive duodenal ulcers compared with omeprazole 40 mg." | 9.10 | Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Scalia, A; Terminella, C, 2002) |
| " pylori-infected peptic ulcer patients were randomly assigned to 1 of 3 groups: RAC4 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 4 days), RAC7 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days), and OAC7 (omeprazole 20mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)." | 9.10 | Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. ( Chen, JH; Chen, TJ; Lee, SC; Wang, GM; Yang, KC, 2003) |
| "To compare the efficacy and safety of two doses of rabeprazole with 20 mg omeprazole in the maintenance treatment of erosive gastro-oesophageal reflux disease over 5 years." | 9.10 | A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. ( Bardhan, KD; Fiocca, R; Humphries, TJ; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2003) |
| "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials." | 9.08 | Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. ( Bassion, S; Cloud, ML; Enas, N; Humphries, TJ, 1998) |
| "Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis." | 9.08 | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998) |
| "This article presents considerations currently under discussion about the probability of HP participation in the ulcer causation as well as information about Rabeprazole efficiency for anti-helicobacter therapy of non-complicated duodenal ulcer (as a result of 7-day anti-helicobacter therapy, the healing of duodenal bulbs was recorded in 82." | 8.82 | [Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)]. ( Vasil'ev, IuB, 2004) |
| "Results of the first week of treatment with rabeprazole in Hp+ and Hp- patients with gastroesophageal reflux disease (GERD) were compared in a large prospective open-label, multicenter, cohort study in general and specialized practices." | 7.73 | Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole? ( Bergmans, P; de Boer, W; de Wit, N; Geldof, H; Hazelhoff, B; Smout, A; Tytgat, G, 2006) |
| "In this multicenter, randomized, double-blind, double-dummy, positive-drug parallel-controlled, phase III study, Chinese patients with duodenal ulcers were randomized 1:1 to receive rabeprazole 10 mg + anaprazole placebo or rabeprazole placebo + anaprazole 20 mg once daily for 4 weeks." | 5.51 | Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study. ( Ding, J; Du, Y; Fan, H; Huang, C; Li, Z; Lyu, N; Pan, X; Pan, Z; Shi, Z; Sun, H; Wang, Q; Zhang, L; Zhu, H, 2022) |
| " Although there was no significant difference between placebo and rabeprazole groups in complete symptom relief for four major dyspeptic symptoms, the satisfactory symptom relief of rabeprazole 20 mg was significantly higher than placebo according to the dyspepsia symptom questionnaire (45." | 5.17 | Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. ( Arakawa, T; Fujimoto, K; Furuta, K; Furuta, T; Haruma, K; Higuchi, K; Hiraishi, H; Hongo, M; Inamori, M; Iwakiri, K; Iwakiri, R; Kanke, K; Kato, M; Kinoshita, Y; Kusano, M; Masuyama, H; Miwa, H; Nagahara, A; Naito, Y; Takahashi, S; Tominaga, K; Watanabe, S, 2013) |
| "The improvement in dysmotility-like dyspepsia symptom score on day 28 was significantly greater in the rabeprazole group (22." | 5.16 | Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia. ( Amemoto, K; Ashida, K; Esaki, H; Fukuchi, T; Hashimoto, T; Isowa, G; Kiyota, K; Majima, K; Morikawa, H; Murotani, M; Ohyama, Y; Oka, H; Sakaguchi, M; Takao, F; Takao, M; Yamashita, H, 2012) |
| "Two hundred and forty Chinese with peptic ulcer disease were randomly assigned to the following regimens: amoxicillin and clarithromycin together with omeprazole (OAC) or rabeprazole (RAC)." | 5.14 | The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people. ( Hu, YM; Li, QS; Mei, Q; Xu, JM; Zhang, L, 2010) |
| "Our study aimed to assess the effectiveness of esomeprazole or rabeprazole in combination with amoxicillin and clarithromycin for the eradication of Helicobacter pylori in Hong Kong non-ulcer dyspepsia (NUD) patients." | 5.14 | Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects. ( Chan, AK; Chan, FK; Chau, TS; Lee, KK; Lee, VW; Ling, TK; Waye, MM, 2010) |
| "To determine if the 4-week efficacy of rabeprazole 20 mg for resolving heartburn and regurgitation symptoms is non-inferior to esomeprazole 40 mg or 20 mg." | 5.14 | Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. ( Eggleston, A; Holtmann, G; Katelaris, PH; Nandurkar, S; Thorpe, P, 2009) |
| "To investigate the effect of Helicobacter pylori eradication on endothelin-1 (ET-1) and nitric oxide (NO) in duodenal ulcer (DU) patients." | 5.11 | Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication. ( Chang, FY; Chen, CY; Lee, SD; Lu, CL; Lu, RH; Luo, JC, 2005) |
| "Two hundred and forty-three patients received rabeprazole (20 mg or 10 mg) or omeprazole (20 mg) once daily for up to 5 years, for gastro-oesophageal reflux disease and 51% completed the whole 5 year period." | 5.11 | Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. ( Fiocca, R; Jacobs, A; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2005) |
| " pylori infection on effectiveness of rabeprazole in primary and secondary care patients with gastro-oesophageal reflux disease." | 5.11 | Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? ( Bergmans, P; Boer, WA; Geldof, H; Hazelhoff, B; Smout, AJ; Tytgat, GN; Wit, NJ, 2004) |
| "To study the efficacy and safety of rabeprazole in peptic ulcer patients alone or combined with anti-Helicobacter pylori (Hp) agents." | 5.11 | [The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients]. ( Lin, SR, 2005) |
| " pylori-positive gastritis or peptic ulcers were randomly assigned to receive 30 mg lansoprazole twice daily (LAC group), 10 mg rabeprazole twice daily (RAC20 group), or 20 mg rabeprazole twice daily (RAC40 group), with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week." | 5.10 | Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. ( Aoyama, N; Kasuga, M; Kita, T; Kuroda, K; Maekawa, S; Miki, I; Okumura, K; Sakaeda, T; Sakai, T; Shirasaka, D; Tamura, T; Wambura, CM, 2003) |
| "To compare the efficacy and safety of two doses of rabeprazole with 20 mg omeprazole in the maintenance treatment of erosive gastro-oesophageal reflux disease over 5 years." | 5.10 | A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. ( Bardhan, KD; Fiocca, R; Humphries, TJ; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2003) |
| "It was to determine the efficacy of rabeprazole at 20 and 40 mg in addition to amoxicillin and clarithromycin in the treatment of active Helicobacter pylori-positive duodenal ulcers compared with omeprazole 40 mg." | 5.10 | Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Scalia, A; Terminella, C, 2002) |
| " pylori-infected peptic ulcer patients were randomly treated with either rabeprazole (10 mg b." | 5.10 | Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. ( Habu, Y; Hayakumo, T; Inokuchi, H; Kawabata, H; Kawai, K; Kimoto, K; Kiyota, K; Kobayashi, M; Kutsumi, H; Mizuno, S; Nakajima, M; Oyasu, K; Tomioka, H, 2003) |
| " pylori-infected peptic ulcer patients were randomly assigned to 1 of 3 groups: RAC4 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 4 days), RAC7 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days), and OAC7 (omeprazole 20mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)." | 5.10 | Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. ( Chen, JH; Chen, TJ; Lee, SC; Wang, GM; Yang, KC, 2003) |
| " pylori-positive patients with peptic ulcer disease were received rabeprazole 10 mg bid, amoxicillin 1,000 mg bid and clarithromycin 500 mg bid for a week." | 5.10 | [A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer]. ( Choi, BK; Chung, JM; Jang, YS; Lee, SH; Lee, YJ; Park, ET; Seol, SY; Yang, SY, 2003) |
| "A total of 170 Helicobacter pylori-positive patients with chronic gastritis were randomized to receive one of the following Helicobacter pylori eradication regimens; OAC (omeprazole 20 mg bd, amoxycillin 750 mg bd and clarithromycin 400 mg bd for 1 week) and RAC (rabeprazole 20 mg bd, amoxycillin 750 mg bd and clarithromycin 400 mg bd for 1 week)." | 5.09 | Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. ( Azuma, T; Dojo, M; Kuriyama, M; Muramatsu, A; Ohtani, M; Saito, T, 2001) |
| "A total of 102 Helicobacter pylori-positive patients with gastric ulcer were randomly allocated to three groups: rabeprazole 10 mg (RAC10), rabeprazole 20 mg (RAC20) or rabeprazole 40 mg (RAC40) plus amoxicillin 750 mg and clarithromycin 200 mg twice daily for 7 days." | 5.09 | Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. ( Asaka, M; Hige, S; Hokari, K; Ishizuka, J; Kagaya, H; Kato, M; Komatsu, Y; Kudo, M; Miyagishima, T; Mizushima, T; Nishikawa, K; Saito, M; Sugiyama, T; Takeda, H, 2001) |
| "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials." | 5.08 | Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. ( Bassion, S; Cloud, ML; Enas, N; Humphries, TJ, 1998) |
| "Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis." | 5.08 | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998) |
| " Rabeprazole is a potent and irreversible inhibitor of H(+)/K(+)-ATPase gastric pump, and it is indicated for the treatment of gastroesophageal reflux disease, Zollinger Ellison syndrome, duodenal and gastric ulcers and for the eradication of Helicobacter pylori in combination with antibiotics." | 4.88 | Rabeprazole for the treatment of acid-related disorders. ( Marelli, S; Pace, F, 2012) |
| "Rabeprazole (Aciphex, Alfence, Pariet) is a proton pump inhibitor (PPI) used for the treatment of adults with conditions requiring a reduction of gastric acid secretion such as erosive or ulcerative gastro-oesophageal reflux disease (GORD), non-erosive reflux disease (NERD), duodenal and gastric ulcers, and pathological hypersecretory conditions including Zollinger-Ellison syndrome (ZES)." | 4.85 | Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. ( Baldwin, CM; Keam, SJ, 2009) |
| " Pharmacodynamic results have also suggested that rabeprazole may be better suited than omeprazole as on-demand therapy for symptomatic gastro-oesophageal reflux disease." | 4.82 | Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole. ( Horn, J, 2004) |
| "This article presents considerations currently under discussion about the probability of HP participation in the ulcer causation as well as information about Rabeprazole efficiency for anti-helicobacter therapy of non-complicated duodenal ulcer (as a result of 7-day anti-helicobacter therapy, the healing of duodenal bulbs was recorded in 82." | 4.82 | [Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)]. ( Vasil'ev, IuB, 2004) |
| " In 8-week studies, among patients with gastro-oesophageal reflux disease (GORD), rabeprazole 20 mg/day or 10mg twice daily was as effective as omeprazole and superior to ranitidine in the healing of GORD." | 4.81 | Rabeprazole: an update of its use in acid-related disorders. ( Carswell, CI; Goa, KL, 2001) |
| "To investigate whether or not CYP2C19 genotype status is associated with cure rate for Helicobacter pylori infection in patients with cirrhosis and peptic ulcer, achieved with 2 weeks of triple therapy with rabeprazole, amoxicillin and clarithromycin." | 3.76 | Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer. ( Lay, CS; Lin, CJ; Lin, JR, 2010) |
| "Results of the first week of treatment with rabeprazole in Hp+ and Hp- patients with gastroesophageal reflux disease (GERD) were compared in a large prospective open-label, multicenter, cohort study in general and specialized practices." | 3.73 | Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole? ( Bergmans, P; de Boer, W; de Wit, N; Geldof, H; Hazelhoff, B; Smout, A; Tytgat, G, 2006) |
| " pylori infected patients with gastric ulcer and duodenal ulcer completed the triple therapy with 10 mg of rabeprazole b." | 3.72 | Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype. ( Bae, JS; Jung, HS; Kim, HJ; Lee, JK; Lee, SB; Park, SJ; Park, SM; Ryu, JK, 2003) |
| " The secondary outcomes were symptom improvement rate, patient compliance, and incidence of adverse events." | 3.30 | Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial. ( Chen, S; Dong, Q; Liu, Y; Shen, W; Shi, Y, 2023) |
| "The optimal dosage of new generation proton pump inhibitors (PPIs) in increasing cure rate of Helicobacter pylori (H." | 3.01 | Network meta-analysis of different dosages of esomeprazole and rabeprazole for the treatment of Helicobacter pylori. ( Dai, X; Gao, C; Wang, Y; Yang, X, 2023) |
| "Rabeprazole (20 mg) has proved similar Helicobacter pylori eradication rates compared with omeprazole (40 mg) when co-administered with of antibiotics (amoxicillin and clarithromycin) for two weeks." | 2.94 | Comparative Study on Effect of Rabeprazole Versus Omeprazole in Acid-peptic Disorder with Helicobacter pylori Infection. ( Amatya, GL; Gurung, SB; Gyawali, P; Kc, SR, 2020) |
| "Patients with early gastric cancers that are limited to gastric mucosa or submucosa usually have an advanced loss of mucosal glandular tissue (glandular atrophy) and are at high risk for subsequent (metachronous) development of new gastric cancer." | 2.87 | Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. ( Cho, SJ; Choi, IJ; Kim, CG; Kim, YI; Kook, MC; Lee, JY; Nam, BH; Park, B, 2018) |
| " The present study was designed to evaluate efficacy of 10-day sequential therapy (SQT) and 14-day standard triple therapy (STT) with four- times-daily dosing of amoxicillin for H." | 2.82 | Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospecti ( Bhanthumkomol, P; Chonprasertsuk, S; Mahachai, V; Phiphatpatthamaamphan, K; Pornthisarn, B; Siramolpiwat, S; Tangaroonsanti, A; Vilaichone, RK, 2016) |
| " There were no significant differences between the groups in regard to the eradication rates and adverse events." | 2.80 | Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea. ( Hong, SN; Kim, JJ; Lee, H; Lee, JH; Lee, YC; Min, BH; Rhee, PL, 2015) |
| "Clarithromycin resistance was determined by the detection of a mutation in 23S rRNA using nested polymerase chain reaction and the direct sequencing of DNA from pretreatment feces." | 2.77 | Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy. ( Deguchi, R; Fukuda, R; Igarashi, M; Koike, J; Matsushima, M; Nakaminami, H; Noguchi, N; Ozawa, H; Rimbara, E; Sasatsu, M; Suzuki, T; Takagi, A, 2012) |
| "Lafutidine is an H2-receptor antagonist with gastroprotective action through capsaicin-sensitive afferent neurons and relatively inexpensive compare to proton-pump inhibitors (PPIs)." | 2.77 | Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study. ( Ando, T; Fujinami, H; Hosokawa, A; Kudo, T; Murakami, J; Nishikawa, J; Ogawa, K; Orihara, T; Sugiyama, T; Takahara, T, 2012) |
| "Rabeprazole clearance was lower in CYP2C19 PMs than in EMs (with average values of 10." | 2.74 | Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. ( Lin, CJ; Uang, YS; Wang, TH; Yang, JC; Yang, YF, 2009) |
| " Subsequent studies should be performed to evaluate antibiotic resistance, doses, dosing intervals, duration of treatment, and safety of these two regimes." | 2.73 | Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. ( Coelho, L; Moretzsohn, L; Sanches, B; Vieira, G, 2008) |
| "A total of 138 distal gastric cancer patients with H." | 2.73 | Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial. ( Bae, JM; Choi, IJ; Hong, EK; Kim, CG; Kim, YW; Kook, MC; Lee, JH; Lee, JY; Park, S; Ryu, KW; Song, HJ, 2008) |
| "Rabeprazole is a proton pump inhibitor which is particularly suitable for use in short-term Helicobacter pylori eradication treatment." | 2.72 | Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. ( Bilardi, C; Dulbecco, P; Giannini, EG; Mamone, M; Mansi, C; Santi, ML; Savarino, V; Testa, R, 2006) |
| "The absorption and bioavailability of proton pump inhibitors is influenced by food intake." | 2.72 | A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study. ( Adachi, K; Azumi, T; Furuta, K; Kinoshita, Y; Koshino, K; Miki, M, 2006) |
| " No significant adverse effects were reported." | 2.72 | Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. ( Abdul-Baki, H; Aoun, E; Araj, GF; Chaar, HF; Kanj, SS; Sharara, AI, 2006) |
| " We determined the therapeutic effects of sofalcone and polaprezinc when combined with rabeprazole, amoxicillin and clarithromycin for Helicobacter pylori infection." | 2.71 | Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. ( Furusu, H; Inoue, K; Isomoto, H; Kohno, S; Ohnita, K; Wen, CY, 2005) |
| "A cross-over study was made in 27 GERD patients (12 males and 15 females)." | 2.71 | [Esomeprasol and rabeprasol effects on esophageal acidification in patients with gastroesophageal reflux disease, intensively metabolizing inhibitors of proton pump]. ( Gushchin, AE; Isakov, VA; Morozov, SV; Shipulin, GA; Tereshchenko, SG; Tsodikova, OM, 2005) |
| " dosing of rabeprazole." | 2.71 | Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus. ( Hall, M; Higbee, A; Mathur, S; Sampliner, RE; Sharma, P; Wani, S; Weston, AP, 2005) |
| "Rabeprazole is a new proton pump inhibitor, which has been reported to induce a faster acid suppression than other drugs of the same category." | 2.71 | Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. ( Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansia, C; Savarino, V; Usai, P; Vigneri, S; Zentilin, P, 2003) |
| "Clarithromycin resistance was detected in all of 8 (100%) RLC-1 failures and in 1 out of 3 (33%) RLC-2 failures." | 2.71 | High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication. ( Branca, G; Cammarota, G; Cannizzaro, O; Cesaro, P; Cianci, R; di Caro, S; Fedeli, P; Gasbarrini, G; Lecca, PG; Martino, A, 2004) |
| "Rabeprazole is a potent proton pump inhibitor that may not be affected as greatly by H." | 2.71 | Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo. ( Chilton, A; Nwokolo, CU; Pounder, RE; Sercombe, J; Usselmann, B; Williams, MP, 2003) |
| " Based on the metabolic and pharmacokinetic differences among other proton pump inhibitors such as omeprazole, lansoprazole and pantoprazole, rabeprazole appears to be the least affected proton pump inhibitor by the CYP2C19-related genetic polymorphism." | 2.70 | Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. ( Furuie, H; Horai, Y; Irie, S; Ishizaki, T; Kimura, M; Koga, Y; Matsuguma, K; Matsui, T; Murakami, M; Nagahama, T; Urae, A; Yao, T, 2001) |
| "Rabeprazole is a new proton pump inhibitor with more potent acid suppressive and anti-Helicobacter effects." | 2.70 | Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. ( Fung, FM; Hu, WH; Hui, CK; Hung, WK; Lai, KC; Lam, SK; Lau, P; Li, KF; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2001) |
| " In this study, we focused on whether 20 mg of rabeprazole is effective in our patient population by comparing that dosage with 40 mg of rabeprazole and 60 mg of lansoprazole." | 2.69 | Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. ( Miwa, H; Murai, T; Nagahara, A; Ogihara, T; Ohkura, R; Ohta, K; Sato, K; Sato, N; Takei, Y; Yamada, T, 2000) |
| "Rabeprazole sodium is a proton pump inhibitor." | 2.69 | Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. ( Fukazawa, K; Ishino, Y; Kawakami, S; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Sugano, K, 2000) |
| " PPI dosage sub-analysis: only esomeprazole 40 mg b." | 2.48 | Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. ( Calvet, X; Gisbert, JP; Linares, PM; McNicholl, AG; Nyssen, OP, 2012) |
| "Gastric acid is pathogenic in many gastrointestinal disorders, such as gastroesophageal reflux disease and peptic ulcer disease." | 2.43 | Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. ( Robinson, M, 2005) |
| " For the better PPI-based treatment, doses and dosing schemes of PPIs should be optimized based on CYP2C19 genotype status." | 2.43 | Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. ( Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M, 2005) |
| "Rabeprazole (Pariet) is a substituted benzimidazole proton pump inhibitor with potent gastric acid suppression properties." | 2.43 | Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. ( Sharara, AI, 2005) |
| "Rabeprazole is a proton pump inhibitor with antisecretory properties." | 2.40 | Rabeprazole. ( Faulds, D; Prakash, A, 1998) |
| "Rabeprazole is an inhibitor of the gastric proton pump." | 2.40 | Rabeprazole: a review of its use in acid-related gastrointestinal disorders. ( Langtry, HD; Markham, A, 1999) |
| "Rabeprazole sodium is a new substituted benzimidazole proton pump inhibitor with several differences compared with existing proton pump inhibitors." | 2.40 | Review article: the pharmacology of rabeprazole. ( Pounder, RE; Williams, MP, 1999) |
| " Here, we present an eradication regimen consisting of four-times-daily dosing (q." | 1.46 | Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan. ( Andoh, A; Ban, H; Furuta, T; Ichikawa, H; Kagami, T; Otsuka, T; Sahara, S; Sugimoto, M, 2017) |
| " Four times daily dosing (q." | 1.40 | Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion. ( Furuta, T; Ichikawa, H; Sahara, S; Sugimoto, K; Sugimoto, M; Uotani, T; Yamade, M, 2014) |
| " Examination of eradication rates according to CAM dosage revealed an eradication rate of 65." | 1.40 | Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). ( Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Masaoaka, T; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A, 2014) |
| "Clarithromycin resistance was uncommon." | 1.33 | Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. ( Campos, A; Cardenas, VM; Chavez, A; El-Zimaity, HM; Graham, DY; Guerrero, L; Opekun, AR, 2006) |
| "pylori in children with type 1 diabetes mellitus improves their metabolic control." | 1.32 | Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes. ( Cammarota, G; Candelli, M; Crea, F; Gasbarrini, A; Gasbarrini, G; Marietti, G; Nista, EC; Petrucci, S; Pignataro, G; Rigante, D; Schiavino, A, 2004) |
| "To achieve more potent and long-lasting acid suppression, different dosage regimens of rabeprazole were compared in relation to the CYP2C19 genotype status." | 1.32 | Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. ( Horikawa, Y; Inoue, M; Kuroiwa, T; Shimatani, T, 2004) |
| "Metronidazole is a good substitute for clarithromycin as the second-line option for children." | 1.32 | Results of triple eradication therapy in Japanese children: a retrospective multicenter study. ( Iinuma, K; Kato, S; Konno, M; Maisawa, S; Nakayama, Y; Shimizu, T; Tajiri, H; Toyoda, S; Yoshimura, N, 2004) |
| "To determine the pharmacokinetic and pharmacodynamic rationale for the optimum regimen of rabeprazole in the treatment of Helicobacter pylori infection in patients who are cytochrome P450 (CYP) 2C19 poor metabolizers or extensive metabolizers." | 1.32 | Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ( Chern, HD; Lin, CJ; Uang, YS; Wang, TH; Yang, JC, 2003) |
| " pylori infection appears to be closely related to the occurrence of nocturnal gastric acid breakthrough during dosing with a proton pump inhibitor." | 1.31 | Helicobacter pylori infection influences nocturnal gastric acid breakthrough. ( Adachi, K; Amano, K; Katsube, T; Kawamura, A; Kinoshita, Y; Uchida, Y; Watanabe, M, 2000) |
| "Rabeprazole is a potent proton pump inhibitor and is mainly reduced to thioether rabeprazole by a non-enzymatic pathway and partially metabolized to demethylated rabeprazole by CYP2C19 in the liver." | 1.31 | Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. ( Furuta, T; Hanai, H; Ishizaki, T; Nakagawa, K; Ohashi, K; Shirai, N; Sugimura, H; Takashima, M; Xiao, F, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (2.42) | 18.2507 |
| 2000's | 166 (57.44) | 29.6817 |
| 2010's | 93 (32.18) | 24.3611 |
| 2020's | 23 (7.96) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, KS | 1 |
| Shah, AK | 1 |
| Bariwal, J | 1 |
| Shelke, SM | 1 |
| Kale, AP | 1 |
| Jagtap, JR | 1 |
| Bhosale, AV | 1 |
| Shao, QQ | 1 |
| Yu, XC | 1 |
| Yu, M | 1 |
| Ma, J | 2 |
| Zhao, JB | 1 |
| Yuan, L | 1 |
| Qi, YB | 1 |
| Hu, RB | 1 |
| Wei, PR | 1 |
| Xiao, W | 1 |
| Lan, L | 1 |
| Jia, BL | 1 |
| Zhang, LZ | 1 |
| Ding, SZ | 1 |
| Wang, JW | 1 |
| Hsu, PI | 8 |
| Lin, MH | 1 |
| Kao, J | 1 |
| Tsay, FW | 3 |
| Wu, IT | 1 |
| Shie, CB | 1 |
| Wu, DC | 10 |
| Dore, MP | 2 |
| Sau, R | 1 |
| Niolu, C | 1 |
| Abbondio, M | 1 |
| Tanca, A | 1 |
| Bibbò, S | 1 |
| Loria, M | 1 |
| Pes, GM | 1 |
| Uzzau, S | 1 |
| Kim, SJ | 1 |
| Jee, SR | 1 |
| Park, MI | 1 |
| Jung, K | 1 |
| Kim, GH | 1 |
| Lee, MW | 1 |
| Lee, J | 1 |
| Jang, JS | 1 |
| Koh, M | 1 |
| Jung, YS | 3 |
| Kim, S | 2 |
| Kim, HY | 2 |
| Noh, SJ | 2 |
| Park, JH | 3 |
| Sohn, CI | 3 |
| Park, CH | 2 |
| Zhu, H | 2 |
| Pan, X | 2 |
| Zhang, L | 4 |
| Sun, H | 1 |
| Fan, H | 1 |
| Pan, Z | 1 |
| Huang, C | 1 |
| Shi, Z | 1 |
| Ding, J | 1 |
| Wang, Q | 1 |
| Du, Y | 1 |
| Lyu, N | 1 |
| Li, Z | 1 |
| Wang, Y | 2 |
| Dai, X | 1 |
| Gao, C | 1 |
| Yang, X | 1 |
| Chen, S | 2 |
| Shen, W | 1 |
| Liu, Y | 2 |
| Dong, Q | 1 |
| Shi, Y | 1 |
| Wu, Y | 1 |
| Liu, X | 2 |
| Liao, O | 1 |
| Lou, G | 1 |
| Li, Y | 4 |
| Wu, H | 1 |
| Du, Q | 1 |
| Ye, J | 1 |
| Han, YY | 1 |
| Zhou, L | 2 |
| Hu, YL | 1 |
| Ding, XW | 1 |
| Long, H | 1 |
| Liu, F | 1 |
| Xu, M | 1 |
| Zhang, ZY | 1 |
| Li, SL | 1 |
| Wang, QY | 1 |
| Su, CX | 1 |
| Chen, Y | 3 |
| Chen, J | 1 |
| Lin, Y | 1 |
| Li, PY | 1 |
| Myint, NPST | 1 |
| Zaw, TT | 1 |
| Sain, K | 1 |
| Waiyan, S | 1 |
| Danta, M | 1 |
| Cooper, D | 1 |
| Aung, NM | 1 |
| Kyi, MM | 1 |
| Hanson, J | 1 |
| Suo, BJ | 1 |
| Tian, XL | 1 |
| Li, CL | 1 |
| Song, ZQ | 1 |
| Kikuchi, S | 1 |
| Nobeyama, Y | 1 |
| Saeki, H | 1 |
| Asahina, A | 1 |
| Gurung, SB | 1 |
| Kc, SR | 1 |
| Gyawali, P | 1 |
| Amatya, GL | 1 |
| Öztürk, K | 2 |
| Kurt, Ö | 1 |
| Çelebi, G | 1 |
| Şarlak, H | 1 |
| Karakaya, MF | 1 |
| Demirci, H | 1 |
| Kılınç, A | 1 |
| Uygun, A | 1 |
| Bang, CS | 1 |
| Lim, H | 1 |
| Jeong, HM | 1 |
| Shin, WG | 1 |
| Choi, JH | 1 |
| Soh, JS | 1 |
| Kang, HS | 1 |
| Yang, YJ | 1 |
| Hong, JT | 1 |
| Shin, SP | 1 |
| Suk, KT | 1 |
| Lee, JJ | 1 |
| Baik, GH | 1 |
| Kim, DJ | 1 |
| Gao, W | 2 |
| Ye, H | 1 |
| Deng, X | 1 |
| Wang, C | 1 |
| Xu, Y | 1 |
| Zhang, X | 2 |
| Cheng, H | 3 |
| Kono, Y | 1 |
| Kusumoto, C | 1 |
| Kiguchi, T | 1 |
| Okada, H | 4 |
| Hwong-Ruey Leow, A | 1 |
| Chang, JV | 1 |
| Goh, KL | 5 |
| Teng, G | 1 |
| Wu, T | 1 |
| Wang, W | 1 |
| Wang, H | 2 |
| Hu, F | 3 |
| Tang, Y | 1 |
| Tang, G | 1 |
| Pan, L | 1 |
| Zhou, S | 1 |
| Wei, Z | 1 |
| Liu, Q | 1 |
| Kodama, M | 7 |
| Okimoto, T | 9 |
| Mizukami, K | 1 |
| Hirashita, Y | 1 |
| Wada, Y | 1 |
| Fukuda, M | 1 |
| Matsunari, O | 1 |
| Okamoto, K | 1 |
| Ogawa, R | 1 |
| Fukuda, K | 1 |
| Kudo, Y | 1 |
| Kawahara, Y | 1 |
| Murakami, K | 9 |
| Xie, J | 1 |
| Fan, L | 1 |
| Xiong, L | 1 |
| Chen, P | 1 |
| Chen, H | 1 |
| Zhao, J | 1 |
| Xu, Z | 2 |
| Geng, L | 1 |
| Xu, W | 1 |
| Gong, S | 1 |
| Maruyama, M | 1 |
| Tanaka, N | 1 |
| Kubota, D | 1 |
| Miyajima, M | 1 |
| Kimura, T | 2 |
| Tokutake, K | 1 |
| Imai, R | 1 |
| Fujisawa, T | 1 |
| Mori, H | 1 |
| Matsuda, Y | 1 |
| Wada, S | 1 |
| Horiuchi, A | 1 |
| Kiyosawa, K | 1 |
| Kawasaki, K | 1 |
| Kurahara, K | 2 |
| Oshiro, Y | 1 |
| Ohtsu, K | 1 |
| Nakamura, S | 3 |
| Fuchigami, T | 1 |
| Matsumoto, T | 4 |
| Sarsenbaeva, AS | 1 |
| Domracheva, EV | 1 |
| Rustamov, MN | 1 |
| Wu, TS | 1 |
| Kuo, CH | 5 |
| Hu, HM | 2 |
| Wu, IC | 4 |
| Wang, SSW | 1 |
| Chen, YH | 1 |
| Su, WW | 1 |
| Kuo, FC | 5 |
| Shimoyama, T | 2 |
| Chinda, D | 1 |
| Sawada, Y | 1 |
| Komai, K | 1 |
| Chiba, H | 1 |
| Saito, Y | 1 |
| Sasaki, Y | 1 |
| Matsuzaka, M | 1 |
| Fukuda, S | 1 |
| Kwon, S | 1 |
| Lee, DH | 12 |
| Kang, JB | 1 |
| Kim, N | 12 |
| Park, YS | 11 |
| Shin, CM | 11 |
| Yoon, H | 7 |
| Choi, YJ | 1 |
| Nagata, Y | 1 |
| Nagasaka, K | 1 |
| Koyama, S | 1 |
| Murase, M | 1 |
| Saito, M | 2 |
| Yazaki, T | 1 |
| Komatsu, N | 1 |
| Murase, T | 1 |
| Uehara, T | 1 |
| Taniuchi, N | 1 |
| Choi, IJ | 2 |
| Kook, MC | 2 |
| Kim, YI | 1 |
| Cho, SJ | 1 |
| Lee, JY | 2 |
| Kim, CG | 2 |
| Park, B | 1 |
| Nam, BH | 1 |
| Robotis, J | 1 |
| Tsiodras, S | 1 |
| Rokkas, T | 1 |
| Xie, Y | 2 |
| Zhu, Z | 1 |
| Wang, J | 2 |
| Zhang, Z | 1 |
| Lu, H | 2 |
| Zeng, Z | 1 |
| Liu, D | 1 |
| Lv, N | 1 |
| Leow, AH | 1 |
| Azmi, AN | 1 |
| Loke, MF | 1 |
| Vadivelu, J | 1 |
| Graham, DY | 3 |
| Gu, L | 1 |
| Li, S | 1 |
| He, Y | 1 |
| Jiang, Y | 1 |
| Peng, Y | 1 |
| Yang, H | 1 |
| Auttajaroon, J | 1 |
| Vilaichone, RK | 3 |
| Chotivitayatarakorn, P | 1 |
| Mahachai, V | 4 |
| Ma, HJ | 1 |
| Wang, JL | 1 |
| Liu, MK | 1 |
| Lu, CY | 3 |
| Yu, FJ | 3 |
| Liu, CJ | 2 |
| Hsu, WH | 4 |
| Su, YC | 1 |
| Chen, A | 4 |
| Chen, JJ | 2 |
| Lee, HJ | 2 |
| Kim, JI | 2 |
| Cheung, DY | 2 |
| Kim, TH | 1 |
| Jun, EJ | 2 |
| Oh, JH | 2 |
| Chung, WC | 2 |
| Kim, BW | 2 |
| Kim, SS | 2 |
| Park, SH | 2 |
| Kim, JK | 1 |
| Iwakiri, R | 2 |
| Tominaga, K | 1 |
| Furuta, K | 2 |
| Inamori, M | 1 |
| Furuta, T | 13 |
| Masuyama, H | 1 |
| Kanke, K | 1 |
| Nagahara, A | 7 |
| Haruma, K | 1 |
| Kinoshita, Y | 5 |
| Higuchi, K | 1 |
| Takahashi, S | 4 |
| Kusano, M | 1 |
| Iwakiri, K | 1 |
| Kato, M | 4 |
| Hongo, M | 2 |
| Hiraishi, H | 1 |
| Watanabe, S | 2 |
| Miwa, H | 7 |
| Naito, Y | 1 |
| Fujimoto, K | 2 |
| Arakawa, T | 1 |
| Yap, PR | 1 |
| Mahadeva, S | 1 |
| Sugimoto, M | 11 |
| Kodaira, C | 2 |
| Nishino, M | 2 |
| Yamade, M | 2 |
| Uotani, T | 3 |
| Sahara, S | 4 |
| Ichikawa, H | 4 |
| Yamada, T | 4 |
| Osawa, S | 1 |
| Sugimoto, K | 2 |
| Watanabe, H | 1 |
| Umemura, K | 1 |
| Sapmaz, F | 1 |
| Kalkan, IH | 1 |
| Güliter, S | 1 |
| Atasoy, P | 1 |
| Morse, AL | 1 |
| Goodman, KJ | 1 |
| Munday, R | 1 |
| Chang, HJ | 1 |
| Morse, JW | 1 |
| Keelan, M | 1 |
| Geary, J | 1 |
| Sander, Vv | 1 |
| Lee, SH | 6 |
| Park, CS | 1 |
| Oh, MJ | 1 |
| Kim, KO | 2 |
| Jang, BI | 1 |
| Jeon, SW | 2 |
| Jung, MK | 2 |
| Park, KS | 2 |
| Kim, ES | 2 |
| Cho, KB | 2 |
| Jung, JT | 2 |
| Kwon, JG | 2 |
| Kim, EY | 2 |
| Kim, WJ | 1 |
| Yang, CH | 2 |
| Onyekwere, CA | 1 |
| Odiagah, JN | 1 |
| Igetei, R | 1 |
| Emanuel, AO | 1 |
| Ekere, F | 1 |
| Smith, S | 1 |
| Zhang, Y | 1 |
| Nishizawa, T | 4 |
| Maekawa, T | 2 |
| Watanabe, N | 1 |
| Harada, N | 2 |
| Hosoda, Y | 1 |
| Yoshinaga, M | 1 |
| Yoshio, T | 2 |
| Ohta, H | 1 |
| Inoue, S | 3 |
| Toyokawa, T | 2 |
| Yamashita, H | 2 |
| Saito, H | 1 |
| Kuwai, T | 2 |
| Katayama, S | 2 |
| Masuda, E | 2 |
| Miyabayashi, H | 1 |
| Nishizawa, Y | 2 |
| Takahashi, M | 4 |
| Suzuki, H | 8 |
| Oh, DH | 1 |
| Kang, KK | 1 |
| Hwang, JH | 6 |
| Jeoung, SH | 2 |
| Kim, JW | 6 |
| Jang, ES | 3 |
| Jung, HC | 4 |
| Chen, MC | 1 |
| Lei, WY | 1 |
| Lin, JS | 1 |
| Yi, CH | 1 |
| Hu, CT | 2 |
| Nykula, TD | 1 |
| Furleta, VV | 1 |
| Zhu, Y | 1 |
| Zhou, H | 1 |
| Lu, ZF | 1 |
| Yang, Z | 1 |
| Shu, X | 1 |
| Guo, XB | 1 |
| Fan, HZ | 1 |
| Tang, JH | 1 |
| Zeng, XP | 1 |
| Wen, JB | 1 |
| Li, XQ | 1 |
| He, XX | 2 |
| Ma, JH | 1 |
| Liu, DS | 1 |
| Huang, CB | 1 |
| Xu, NJ | 1 |
| Wang, NR | 1 |
| Lu, NH | 1 |
| Ren, L | 1 |
| Li, HY | 1 |
| Zhu, LY | 1 |
| Xu, XQ | 1 |
| Gu, LY | 1 |
| Ge, ZZ | 1 |
| Li, XB | 1 |
| Chung, KH | 1 |
| Jin, E | 1 |
| Cho, Y | 1 |
| Seo, JY | 2 |
| Jeong, SH | 4 |
| Lee, H | 1 |
| Hong, SN | 1 |
| Min, BH | 1 |
| Lee, JH | 3 |
| Rhee, PL | 1 |
| Lee, YC | 1 |
| Kim, JJ | 2 |
| Kawai, T | 3 |
| Sasaki, H | 1 |
| Asaoka, D | 1 |
| Matsuhisa, T | 1 |
| Masaoaka, T | 1 |
| Suzuki, M | 3 |
| Ito, M | 1 |
| Kurihara, N | 1 |
| Omata, F | 1 |
| Mizuno, S | 2 |
| Torii, A | 1 |
| Kawakami, K | 3 |
| Ohkusa, T | 2 |
| Tokunaga, K | 3 |
| Mine, T | 1 |
| Sakaki, N | 1 |
| Ierardi, E | 11 |
| Giangaspero, A | 1 |
| Losurdo, G | 1 |
| Giorgio, F | 1 |
| Amoruso, A | 2 |
| De Francesco, V | 12 |
| Di Leo, A | 3 |
| Principi, M | 1 |
| Lee, JS | 1 |
| Kimko, H | 1 |
| Thyssen, A | 1 |
| Mould, DR | 1 |
| Mannaert, E | 1 |
| Treem, WR | 1 |
| Ben Chaabane, N | 1 |
| Al-Adhba, HS | 1 |
| Mitsui, Y | 1 |
| Kagemoto, K | 1 |
| Itagaki, T | 1 |
| Naruse, K | 1 |
| Muguruma, N | 1 |
| Takayama, T | 1 |
| Başyiğit, S | 2 |
| Kefeli, A | 1 |
| Yeniova, AÖ | 1 |
| Uzman, M | 2 |
| Nazlıgül, Y | 2 |
| Aktaş, B | 2 |
| Yüksel, O | 1 |
| Akkan, T | 1 |
| Atbaşı, ST | 1 |
| Yılmaz, B | 1 |
| Şimşek, G | 1 |
| Hwang, JJ | 4 |
| Lee, AR | 3 |
| Kagami, T | 2 |
| Altun, B | 1 |
| Jheng, GH | 1 |
| Shih, HY | 1 |
| Wu, MC | 1 |
| Bair, MJ | 2 |
| Molina-Infante, J | 1 |
| Gisbert, JP | 6 |
| Kim, J | 1 |
| Chen, KY | 1 |
| Lin, TJ | 1 |
| Lin, CL | 1 |
| Lee, HC | 1 |
| Wang, CK | 1 |
| Lim, JH | 2 |
| Lee, ST | 2 |
| Song, IS | 4 |
| Ormeci, A | 1 |
| Emrence, Z | 1 |
| Baran, B | 1 |
| Gokturk, S | 1 |
| Soyer, OM | 1 |
| Evirgen, S | 1 |
| Akyuz, F | 1 |
| Karaca, C | 1 |
| Besisik, F | 1 |
| Kaymakoglu, S | 1 |
| Ustek, D | 1 |
| Demir, K | 1 |
| Song, Z | 1 |
| Suo, B | 1 |
| Suzuki, S | 1 |
| Gotoda, T | 1 |
| Kusano, C | 1 |
| Iwatsuka, K | 1 |
| Moriyama, M | 1 |
| Ban, H | 1 |
| Otsuka, T | 1 |
| Andoh, A | 1 |
| Phiphatpatthamaamphan, K | 1 |
| Siramolpiwat, S | 1 |
| Tangaroonsanti, A | 1 |
| Chonprasertsuk, S | 1 |
| Bhanthumkomol, P | 1 |
| Pornthisarn, B | 2 |
| Shiratori, S | 1 |
| Mabe, K | 1 |
| Yoshii, S | 1 |
| Takakuwa, Y | 1 |
| Sato, M | 2 |
| Nakamura, M | 2 |
| Kudo, T | 3 |
| Asaka, M | 4 |
| Sakamoto, N | 1 |
| Kajihara, Y | 1 |
| Mizuki, I | 1 |
| de Artaza Varasa, T | 1 |
| Valle Muñoz, J | 1 |
| Pérez-Grueso, MJ | 1 |
| García Vela, A | 1 |
| Martín Escobedo, R | 1 |
| Rodríguez Merlo, R | 1 |
| Cuena Boy, R | 1 |
| Carrobles Jiménez, JM | 1 |
| Hong, EJ | 1 |
| Park, DI | 2 |
| Oh, SJ | 1 |
| Song, MJ | 1 |
| Choi, WH | 1 |
| Hong, CH | 1 |
| Kim, HJ | 3 |
| Cho, YK | 2 |
| Shon, CI | 1 |
| Jeon, WK | 2 |
| Kim, BI | 2 |
| Nakagawa, I | 1 |
| Iwasaki, E | 1 |
| Masaoka, T | 1 |
| Hibi, T | 2 |
| Wang, XY | 2 |
| Shen, SR | 2 |
| Zhao, F | 1 |
| Yang, Y | 1 |
| Wang, X | 1 |
| Shi, R | 2 |
| Huang, Z | 1 |
| Zhang, G | 2 |
| Sanches, B | 1 |
| Coelho, L | 1 |
| Moretzsohn, L | 1 |
| Vieira, G | 1 |
| Eggleston, A | 1 |
| Katelaris, PH | 1 |
| Nandurkar, S | 1 |
| Thorpe, P | 1 |
| Holtmann, G | 1 |
| Hu, FL | 1 |
| Pellicano, R | 1 |
| Osipenko, MF | 2 |
| Konstantinov, VI | 1 |
| Moiseenko, EE | 1 |
| Bikbulatova, EA | 2 |
| Yang, JC | 2 |
| Yang, YF | 1 |
| Uang, YS | 2 |
| Lin, CJ | 3 |
| Wang, TH | 2 |
| Soto, A | 1 |
| García, A | 1 |
| González, CL | 1 |
| Baldwin, CM | 1 |
| Keam, SJ | 1 |
| Aydin, A | 1 |
| Oruc, N | 1 |
| Turan, I | 1 |
| Ozutemiz, O | 1 |
| Tuncyurek, M | 1 |
| Musoglu, A | 1 |
| Zullo, A | 11 |
| Hassan, C | 10 |
| Cristofari, F | 1 |
| Iegri, C | 1 |
| Kwon, JH | 1 |
| Song, BJ | 1 |
| Lee, JW | 1 |
| Lay, CS | 1 |
| Lin, JR | 1 |
| Wang, SS | 1 |
| Weng, BC | 1 |
| Li, CJ | 1 |
| Hung, WC | 1 |
| Yang, YC | 1 |
| Wang, WM | 2 |
| Lee, VW | 1 |
| Chau, TS | 1 |
| Chan, AK | 1 |
| Lee, KK | 1 |
| Waye, MM | 1 |
| Ling, TK | 1 |
| Chan, FK | 1 |
| Konno, T | 1 |
| Motoori, S | 1 |
| Iwamoto, N | 1 |
| Miyazawa, T | 1 |
| Saito, S | 1 |
| Kitagawa, N | 1 |
| Saisho, H | 1 |
| Furuse, J | 1 |
| Itabashi, M | 1 |
| Mei, Q | 1 |
| Li, QS | 1 |
| Hu, YM | 1 |
| Xu, JM | 1 |
| Qiu, Y | 1 |
| Tang, Q | 1 |
| Qian, B | 1 |
| Yao, L | 1 |
| Hori, K | 1 |
| Tamura, T | 2 |
| Kurata, M | 1 |
| Kondo, T | 1 |
| Goto, Y | 1 |
| Kamiya, Y | 1 |
| Kawai, S | 1 |
| Hamajima, N | 1 |
| Mansour, NM | 1 |
| Hashash, JG | 1 |
| El-Halabi, M | 1 |
| Ghaith, O | 1 |
| Maasri, K | 1 |
| Sukkarieh, I | 1 |
| Malli, A | 1 |
| Sharara, AI | 4 |
| Oh, HS | 1 |
| Cho, YR | 1 |
| Cho, HJ | 1 |
| Ugajin, T | 1 |
| Miyatani, H | 1 |
| Matsumoto, S | 1 |
| Takamatsu, T | 1 |
| Fukunishi, M | 1 |
| Yoshida, Y | 3 |
| Dobashi, Y | 1 |
| Baba, S | 1 |
| Oishi, Y | 1 |
| Watanabe, Y | 1 |
| Oikawa, R | 1 |
| Morita, R | 1 |
| Hiraishi, T | 1 |
| Maehata, T | 1 |
| Nagase, Y | 1 |
| Fukuda, Y | 2 |
| Nakazawa, M | 1 |
| Ishigouoka, S | 1 |
| Hattori, N | 1 |
| Toyota, M | 1 |
| Niwa, H | 1 |
| Itoh, F | 1 |
| Fujioka, T | 10 |
| Aoyama, N | 3 |
| Sakai, K | 1 |
| Miwa, Y | 1 |
| Kudo, M | 2 |
| Kawashima, J | 1 |
| Matsubara, Y | 1 |
| Miwa, J | 1 |
| Yakabi, K | 1 |
| Park, HG | 1 |
| Seo, HE | 1 |
| Deguchi, R | 1 |
| Nakaminami, H | 1 |
| Rimbara, E | 2 |
| Noguchi, N | 2 |
| Sasatsu, M | 2 |
| Suzuki, T | 2 |
| Matsushima, M | 1 |
| Koike, J | 1 |
| Igarashi, M | 1 |
| Ozawa, H | 1 |
| Fukuda, R | 1 |
| Takagi, A | 1 |
| Karatapanis, S | 1 |
| Georgopoulos, SD | 1 |
| Papastergiou, V | 1 |
| Skorda, L | 1 |
| Papantoniou, N | 1 |
| Lisgos, P | 1 |
| Kouvidou, C | 1 |
| Fragkou, P | 1 |
| Mentis, A | 1 |
| Takeshima, F | 1 |
| Senoo, T | 1 |
| Matsushima, K | 1 |
| Akazawa, Y | 1 |
| Yamaguchi, N | 1 |
| Shiozawa, K | 1 |
| Ohnita, K | 2 |
| Ichikawa, T | 1 |
| Isomoto, H | 4 |
| Nakao, K | 1 |
| Manikam, J | 1 |
| Qua, CS | 1 |
| Sakaguchi, M | 1 |
| Takao, M | 1 |
| Ohyama, Y | 1 |
| Oka, H | 1 |
| Fukuchi, T | 1 |
| Ashida, K | 1 |
| Murotani, M | 2 |
| Majima, K | 1 |
| Morikawa, H | 1 |
| Hashimoto, T | 1 |
| Kiyota, K | 2 |
| Esaki, H | 1 |
| Amemoto, K | 1 |
| Isowa, G | 1 |
| Takao, F | 1 |
| Choi, HS | 2 |
| Chun, HJ | 1 |
| Keum, B | 1 |
| Seo, YS | 1 |
| Kim, YS | 1 |
| Jeen, YT | 1 |
| Um, SH | 1 |
| Lee, HS | 1 |
| Kim, CD | 1 |
| Ryu, HS | 1 |
| Ohara, M | 1 |
| Kawanishi, M | 1 |
| Noguchi, K | 1 |
| Katsushima, S | 1 |
| Tsuruta, H | 1 |
| Tanaka, M | 1 |
| Kawamura, N | 1 |
| Fujinami, H | 1 |
| Ando, T | 1 |
| Nishikawa, J | 1 |
| Ogawa, K | 2 |
| Hosokawa, A | 1 |
| Orihara, T | 1 |
| Murakami, J | 1 |
| Takahara, T | 1 |
| Sugiyama, T | 3 |
| Kongchayanun, C | 1 |
| Amornsawadwattana, S | 1 |
| McNicholl, AG | 1 |
| Linares, PM | 1 |
| Nyssen, OP | 1 |
| Calvet, X | 5 |
| Marelli, S | 1 |
| Pace, F | 2 |
| Sugizaki, K | 1 |
| Sakata, Y | 1 |
| Arai, T | 1 |
| Furuhata, Y | 1 |
| Iinuma, N | 1 |
| Choi, C | 1 |
| Jo, HJ | 1 |
| Inaba, T | 2 |
| Mizuno, M | 3 |
| Kawai, K | 2 |
| Yokota, K | 3 |
| Oguma, K | 3 |
| Miyoshi, M | 2 |
| Take, S | 2 |
| Tsuji, T | 2 |
| Vasil'ev, IuV | 2 |
| Kas'ianenko, VI | 1 |
| Minushkin, ON | 1 |
| Zverkov, IV | 1 |
| Aronova, OV | 1 |
| Shuleshova, AG | 1 |
| Faleo, D | 2 |
| Panella, C | 7 |
| Margiotta, M | 3 |
| Sato, R | 6 |
| Nasu, M | 5 |
| Kagawa, J | 3 |
| Sato, S | 2 |
| Abe, H | 1 |
| Arita, T | 2 |
| Ogiahara, S | 1 |
| Handa, Y | 1 |
| Moriyasu, F | 2 |
| Go, MF | 1 |
| Catalano, F | 1 |
| Terminella, C | 1 |
| Branciforte, G | 1 |
| Bentivegna, C | 1 |
| Brogna, A | 1 |
| Scalia, A | 1 |
| Kawabata, H | 1 |
| Habu, Y | 1 |
| Tomioka, H | 1 |
| Kutsumi, H | 1 |
| Kobayashi, M | 1 |
| Oyasu, K | 1 |
| Hayakumo, T | 1 |
| Nakajima, M | 1 |
| Kimoto, K | 1 |
| Inokuchi, H | 1 |
| Miki, I | 1 |
| Sakai, T | 1 |
| Shirasaka, D | 1 |
| Wambura, CM | 1 |
| Maekawa, S | 1 |
| Kuroda, K | 1 |
| Kita, T | 1 |
| Sakaeda, T | 1 |
| Okumura, K | 1 |
| Kasuga, M | 1 |
| Thjodleifsson, B | 3 |
| Rindi, G | 2 |
| Fiocca, R | 2 |
| Humphries, TJ | 3 |
| Morocutti, A | 2 |
| Miller, N | 2 |
| Bardhan, KD | 1 |
| Wong, WM | 4 |
| Gu, Q | 2 |
| Lam, SK | 4 |
| Fung, FM | 4 |
| Lai, KC | 4 |
| Hu, WH | 2 |
| Yee, YK | 2 |
| Chan, CK | 3 |
| Xia, HH | 3 |
| Yuen, MF | 3 |
| Wong, BC | 5 |
| Khorrami, S | 1 |
| Pajares, JM | 1 |
| Williams, MP | 2 |
| Usselmann, B | 1 |
| Chilton, A | 1 |
| Sercombe, J | 1 |
| Nwokolo, CU | 1 |
| Pounder, RE | 2 |
| Vaira, D | 3 |
| Vakil, N | 2 |
| Gatta, L | 2 |
| Ricci, C | 3 |
| Menegatti, M | 1 |
| Tampieri, A | 1 |
| Perna, F | 2 |
| Rinaldi, V | 1 |
| Perri, F | 1 |
| Papadìa, C | 1 |
| Fornari, F | 1 |
| Pilati, S | 1 |
| Mete, LS | 1 |
| Merla, A | 1 |
| Potì, R | 1 |
| Marinone, G | 1 |
| Savioli, A | 1 |
| Campo, SM | 1 |
| Miglioli, M | 1 |
| Morini, S | 10 |
| Hawkey, CJ | 2 |
| Atherton, JC | 2 |
| Treichel, HC | 1 |
| Ravic, M | 1 |
| Mario, FD | 1 |
| Dal Bo, N | 2 |
| Aragona, G | 2 |
| Moussa, AM | 1 |
| Iori, V | 2 |
| Cavestro, GM | 2 |
| Pilotto, A | 2 |
| Leandro, G | 2 |
| Franceschi, M | 1 |
| Rugge, M | 1 |
| Franze, A | 2 |
| Miyazawa, M | 2 |
| Nagahashi, S | 2 |
| Bessho, M | 1 |
| Nagata, H | 1 |
| Miura, S | 1 |
| Ishii, H | 2 |
| Lorenzetti, R | 2 |
| Marignani, M | 1 |
| Angeletti, S | 1 |
| Chern, HD | 1 |
| Inoue, K | 3 |
| Furusu, H | 3 |
| Enjoji, A | 1 |
| Fujimoto, C | 1 |
| Yamakawa, M | 1 |
| Hirakata, Y | 1 |
| Omagari, K | 2 |
| Mizuta, Y | 2 |
| Murase, K | 2 |
| Shimada, S | 1 |
| Murata, I | 2 |
| Kohno, S | 3 |
| Pankova, LIu | 1 |
| Vergara, M | 2 |
| Vallve, M | 2 |
| Scaccianoce, G | 2 |
| Piglionica, D | 2 |
| Choi, BK | 1 |
| Yang, SY | 1 |
| Park, ET | 1 |
| Jang, YS | 1 |
| Lee, YJ | 1 |
| Seol, SY | 1 |
| Chung, JM | 1 |
| Kositchaiwat, C | 1 |
| Ovartlarnporn, B | 1 |
| Kachintorn, U | 1 |
| Atisook, K | 1 |
| Borody, TJ | 1 |
| Ashman, O | 1 |
| Di Mario, F | 1 |
| Cavallaro, L | 1 |
| Comparato, G | 1 |
| Ishiki, K | 2 |
| Nagahara, Y | 2 |
| Yoshida, T | 1 |
| Yamamoto, K | 1 |
| Shiratori, Y | 1 |
| Shirai, N | 8 |
| Ohashi, K | 3 |
| Ishizaki, T | 6 |
| Gambaro, C | 1 |
| Bilardi, C | 3 |
| Dulbecco, P | 4 |
| Iiritano, E | 1 |
| Zentilin, P | 1 |
| Mansia, C | 1 |
| Usai, P | 1 |
| Vigneri, S | 1 |
| Savarino, V | 5 |
| Shimatani, T | 3 |
| Inoue, M | 3 |
| Kuroiwa, T | 2 |
| Horikawa, Y | 1 |
| Lee, SB | 1 |
| Park, SJ | 1 |
| Ryu, JK | 1 |
| Lee, JK | 1 |
| Bae, JS | 1 |
| Jung, HS | 1 |
| Park, SM | 1 |
| Cammarota, G | 5 |
| Cianci, R | 2 |
| Cannizzaro, O | 2 |
| Martino, A | 1 |
| Fedeli, P | 1 |
| Lecca, PG | 1 |
| di Caro, S | 1 |
| Cesaro, P | 1 |
| Branca, G | 1 |
| Gasbarrini, G | 5 |
| Marangi, S | 2 |
| Burattini, O | 2 |
| Berloco, P | 1 |
| Russo, F | 2 |
| Barone, M | 1 |
| Minenna, MF | 2 |
| Stoppino, V | 4 |
| Francavilla, A | 1 |
| Yang, KC | 1 |
| Wang, GM | 1 |
| Chen, JH | 1 |
| Chen, TJ | 1 |
| Lee, SC | 1 |
| Zhao, YH | 1 |
| Hao, YT | 1 |
| Kornienko, EA | 1 |
| Klochko, OG | 1 |
| Candelli, M | 3 |
| Rigante, D | 1 |
| Marietti, G | 1 |
| Nista, EC | 2 |
| Crea, F | 1 |
| Schiavino, A | 1 |
| Pignataro, G | 1 |
| Petrucci, S | 1 |
| Gasbarrini, A | 4 |
| Della Valle, N | 2 |
| Muscatiello, N | 1 |
| Chaar, HF | 2 |
| Racoubian, E | 1 |
| Moukhachen, O | 1 |
| Barada, KA | 1 |
| Mourad, FH | 1 |
| Araj, GF | 2 |
| Pietrini, L | 1 |
| Winn, S | 1 |
| Monno, R | 2 |
| Lanza, F | 1 |
| Schwartz, H | 1 |
| Barth, J | 2 |
| Belson, G | 1 |
| Abudayyeh, S | 1 |
| Osato, MS | 1 |
| El-Zimaity, HM | 2 |
| Wit, NJ | 1 |
| Boer, WA | 1 |
| Geldof, H | 2 |
| Hazelhoff, B | 2 |
| Bergmans, P | 2 |
| Tytgat, GN | 1 |
| Smout, AJ | 1 |
| Bosques-Padilla, FJ | 1 |
| Garza-González, E | 1 |
| Calderón-Lozano, IE | 1 |
| Reed-SanRoman, G | 1 |
| de Ariño Suárez, M | 1 |
| Valdovinos-Díaz, MA | 1 |
| Orozco-Gámiz, A | 1 |
| Blancas-Valencia, JM | 1 |
| Tamayo-de la Cuesta, JL | 1 |
| Horn, J | 1 |
| Robinson, M | 2 |
| Vasil'ev, IuB | 1 |
| Kato, S | 1 |
| Konno, M | 1 |
| Maisawa, S | 1 |
| Tajiri, H | 1 |
| Yoshimura, N | 1 |
| Shimizu, T | 1 |
| Toyoda, S | 1 |
| Nakayama, Y | 1 |
| Iinuma, K | 1 |
| Cremonini, F | 2 |
| Cazzato, IA | 1 |
| Zocco, MA | 2 |
| Franceschi, F | 1 |
| Watanabe, K | 3 |
| Tanaka, A | 1 |
| Imase, K | 1 |
| Sugano, H | 1 |
| Kai, A | 1 |
| Ishida, H | 1 |
| Itoh, T | 1 |
| Chang, FY | 1 |
| Chen, CY | 1 |
| Lu, CL | 1 |
| Luo, JC | 1 |
| Lu, RH | 1 |
| Lee, SD | 1 |
| Maev, IV | 1 |
| Gadzhieva, MG | 1 |
| Coelho, LG | 1 |
| Moretzsohn, LD | 1 |
| Vieira, WL | 1 |
| Gallo, MA | 1 |
| Passos, MC | 1 |
| Cindr, JM | 1 |
| Cerqueira, MC | 1 |
| Vitiello, L | 1 |
| Ribeiro, ML | 1 |
| Mendonça, S | 1 |
| Pedrazzoli-Júnior, J | 1 |
| Castro, LP | 1 |
| Wen, CY | 1 |
| Wang, HH | 1 |
| Chou, JW | 1 |
| Liao, KF | 1 |
| Lin, ZY | 1 |
| Lai, HC | 1 |
| Hsu, CH | 1 |
| Chen, CB | 1 |
| Morozov, SV | 1 |
| Tsodikova, OM | 1 |
| Isakov, VA | 1 |
| Tereshchenko, SG | 1 |
| Gushchin, AE | 1 |
| Shipulin, GA | 1 |
| Jacobs, A | 1 |
| Lin, SR | 1 |
| Tsuji, S | 1 |
| Kawano, S | 2 |
| Huang, J | 1 |
| Tong, TS | 2 |
| Cheung, KL | 1 |
| Ho, VY | 1 |
| Chan, AO | 2 |
| Hui, CK | 2 |
| Bernabucci, V | 1 |
| Cavina, M | 1 |
| Nakamura, A | 2 |
| Hishida, A | 2 |
| Annese, V | 1 |
| Prada, A | 1 |
| Zambelli, A | 1 |
| Casalini, S | 1 |
| Nardini, P | 1 |
| Bianchi Porro, G | 1 |
| Giannini, EG | 3 |
| Malfatti, F | 1 |
| Botta, F | 1 |
| Polegato, S | 1 |
| Testa, E | 1 |
| Fumagalli, A | 1 |
| Mamone, M | 3 |
| Testa, R | 3 |
| Ducons, J | 1 |
| Bujanda, L | 1 |
| Bory, F | 1 |
| Montserrat, A | 1 |
| Wang, F | 1 |
| Jia, Y | 1 |
| Xu, CX | 1 |
| Tang, WL | 1 |
| Liu, SJ | 1 |
| Chen, X | 1 |
| Wani, S | 1 |
| Sampliner, RE | 1 |
| Weston, AP | 1 |
| Mathur, S | 1 |
| Hall, M | 1 |
| Higbee, A | 1 |
| Sharma, P | 1 |
| Lim, PW | 1 |
| Nakmura, A | 1 |
| Nakagawa, S | 1 |
| Shimizu, Y | 1 |
| Nakagawa, M | 1 |
| Santi, ML | 2 |
| Mansi, C | 2 |
| Cardenas, VM | 1 |
| Opekun, AR | 1 |
| Campos, A | 1 |
| Chavez, A | 1 |
| Guerrero, L | 1 |
| Xu, J | 2 |
| Mieno, H | 1 |
| Tazuma, S | 2 |
| Troiani, L | 1 |
| Stella, F | 1 |
| Abe, T | 1 |
| Onoda, N | 1 |
| Katsuragi, K | 1 |
| Sawada, T | 1 |
| Maeda, K | 1 |
| Mino, A | 1 |
| Ohira, M | 1 |
| Ishikawa, T | 1 |
| Wakasa, K | 1 |
| Hirakawa, K | 1 |
| Walshe, V | 1 |
| O'Morain, C | 1 |
| Bennett, K | 1 |
| Keeling, PW | 1 |
| Barry, M | 1 |
| Wang, JD | 1 |
| Wong, KW | 1 |
| Moriwaki, M | 1 |
| Padol, S | 1 |
| Yuan, Y | 1 |
| Thabane, M | 1 |
| Padol, IT | 1 |
| Hunt, RH | 1 |
| Aoun, E | 1 |
| Abdul-Baki, H | 1 |
| Kanj, SS | 1 |
| Gon, S | 1 |
| Irie, Y | 1 |
| Ariizumi, K | 1 |
| Ohara, S | 1 |
| Koike, T | 1 |
| Inomata, Y | 1 |
| Iijima, K | 1 |
| Sekine, H | 1 |
| Noguchi, M | 1 |
| Sugiyama, K | 1 |
| Eda, Y | 1 |
| Kayaba, S | 1 |
| Kawamura, M | 1 |
| Shimosegawa, T | 1 |
| Savarino, E | 1 |
| de Boer, W | 1 |
| de Wit, N | 1 |
| Smout, A | 1 |
| Tytgat, G | 1 |
| Miki, M | 1 |
| Adachi, K | 4 |
| Azumi, T | 1 |
| Koshino, K | 1 |
| Nikol'skaia, KA | 1 |
| Garza González, E | 1 |
| Giasi González, E | 1 |
| Martínez Vázquez, MA | 1 |
| Pérez Pérez, GI | 1 |
| González, GM | 1 |
| Maldonado Garza, HJ | 1 |
| Bosques Padilla, FJ | 1 |
| Kuwayama, H | 2 |
| Hirai, Y | 1 |
| Belousov, IuB | 1 |
| Karpov, OI | 1 |
| Belousov, DIu | 1 |
| Beketov, AS | 1 |
| Mikinori, K | 1 |
| Takei, K | 1 |
| Itoi, T | 1 |
| Takagi, Y | 1 |
| Aoki, T | 1 |
| Watanebe, K | 1 |
| Matsumoto, Y | 1 |
| Ikuma, M | 1 |
| Kajimura, M | 1 |
| Manes, G | 1 |
| Efrati, C | 1 |
| Maconi, G | 1 |
| Cannaviello, C | 1 |
| Song, HJ | 1 |
| Hong, EK | 1 |
| Park, S | 1 |
| Ryu, KW | 1 |
| Kim, YW | 1 |
| Bae, JM | 1 |
| Thong-Ngam, D | 1 |
| Wang, TE | 1 |
| Chang, WH | 1 |
| Wu, JY | 1 |
| Hwang, SJ | 1 |
| Park, JS | 1 |
| Livzan, MA | 1 |
| Kononov, AV | 1 |
| Mozgovoĭ, SI | 1 |
| Peng, NJ | 1 |
| Tseng, HH | 1 |
| Lo, GH | 1 |
| Lai, KH | 1 |
| Takimoto, T | 1 |
| Ido, K | 1 |
| Taniguchi, Y | 1 |
| Satoh, K | 2 |
| Saifuku, K | 2 |
| Kihira, K | 2 |
| Kimura, K | 2 |
| Prakash, A | 1 |
| Faulds, D | 1 |
| Cloud, ML | 1 |
| Enas, N | 1 |
| Bassion, S | 1 |
| Stack, WA | 1 |
| Knifton, A | 1 |
| Thirlwell, D | 1 |
| Cockayne, A | 1 |
| Jenkins, D | 1 |
| Ohkura, R | 5 |
| Murai, T | 2 |
| Sato, K | 3 |
| Hirai, S | 1 |
| Sato, N | 6 |
| Langtry, HD | 1 |
| Markham, A | 1 |
| Ohta, K | 1 |
| Takei, Y | 1 |
| Ogihara, T | 1 |
| Ohning, GV | 1 |
| Barbuti, RC | 1 |
| Kovacs, TO | 1 |
| Sytnik, B | 1 |
| Walsh, JH | 1 |
| Kurosawa, A | 2 |
| Iida, N | 1 |
| Katsube, T | 1 |
| Kawamura, A | 1 |
| Amano, K | 1 |
| Uchida, Y | 1 |
| Watanabe, M | 1 |
| Kawakami, S | 1 |
| Fukazawa, K | 1 |
| Ishino, Y | 1 |
| Sugano, K | 1 |
| Cuoco, L | 1 |
| Pirozzi, G | 1 |
| Armuzzi, A | 2 |
| Santarelli, L | 1 |
| Arancio, F | 1 |
| Morikawa, T | 1 |
| Nishiyama, T | 1 |
| Hizawa, K | 1 |
| Nakahara, T | 1 |
| Yano, Y | 1 |
| Inuzuka, S | 1 |
| Akagi, K | 1 |
| Bartolozzi, F | 1 |
| Canducci, F | 1 |
| Ojetti, V | 1 |
| Anti, M | 1 |
| De Lorenzo , A | 1 |
| Pola, P | 1 |
| Satoh, R | 1 |
| Lüth, S | 1 |
| Teyssen, S | 1 |
| Kölbel, CB | 1 |
| Singer, MV | 1 |
| Horai, Y | 1 |
| Kimura, M | 1 |
| Furuie, H | 1 |
| Matsuguma, K | 1 |
| Irie, S | 1 |
| Koga, Y | 1 |
| Nagahama, T | 1 |
| Murakami, M | 1 |
| Matsui, T | 1 |
| Yao, T | 1 |
| Urae, A | 1 |
| Bardou, M | 1 |
| Ohara, T | 1 |
| Goshi, S | 1 |
| Taneike, I | 1 |
| Tamura, Y | 1 |
| Zhang, HM | 1 |
| Yamamoto, T | 1 |
| Hojo, M | 1 |
| Takashima, M | 1 |
| Xiao, F | 1 |
| Hanai, H | 1 |
| Nakagawa, K | 1 |
| Sugimura, H | 1 |
| Maga, T | 1 |
| Torigoe, T | 1 |
| Nasu, J | 1 |
| Baranskaia, EK | 1 |
| Hokari, K | 1 |
| Miyagishima, T | 1 |
| Nishikawa, K | 1 |
| Ishizuka, J | 1 |
| Komatsu, Y | 1 |
| Mizushima, T | 1 |
| Kagaya, H | 1 |
| Hige, S | 1 |
| Takeda, H | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Kusano, Y | 1 |
| Esaki, M | 1 |
| Fukuda, T | 1 |
| Hung, WK | 1 |
| Yip, AW | 1 |
| Szeto, ML | 1 |
| Li, KF | 1 |
| Lau, P | 1 |
| Starostin, BD | 1 |
| Carswell, CI | 1 |
| Goa, KL | 1 |
| Dojo, M | 1 |
| Azuma, T | 1 |
| Saito, T | 1 |
| Ohtani, M | 1 |
| Muramatsu, A | 1 |
| Kuriyama, M | 1 |
| Hahne, W | 1 |
| Kitahora, T | 1 |
| Suzuki, K | 1 |
| Fu, HY | 1 |
| Tanimura, H | 1 |
| Ishitobi, H | 1 |
| Yoshino, J | 1 |
| Sato, H | 1 |
| Abe, K | 1 |
| Oshima, N | 1 |
| Kawashima, K | 1 |
| Hamamoto, N | 1 |
| Moritani, M | 1 |
| Mak, R | 1 |
| Ishihara, S | 1 |
| Kawauchi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Helicobacter Pylori Eradication on Glandular Atrophy and Metachronous Cancer in Patients Undergoing Endoscopic Mucosal Resection for Gastric Cancer[NCT02407119] | Phase 3 | 470 participants (Actual) | Interventional | 2003-06-30 | Active, not recruiting | ||
| Bismuth Quadruple Therapy in Helicobacter Pylori Rescue Therapy: A Multicenter Randomized Non-Inferiority Trial of Different Tetracycline Doses and Frequencies.[NCT05802888] | Phase 4 | 260 participants (Anticipated) | Interventional | 2023-03-12 | Recruiting | ||
| Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Multicenter Randomized Clinical Trial of Different Tetracycline Doses and Frequencies.[NCT05431075] | Phase 4 | 407 participants (Anticipated) | Interventional | 2022-07-31 | Not yet recruiting | ||
| Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy: A Multicenter Randomized Non-Inferiority Trial of Different Tetracycline Doses and Frequencies.[NCT05432115] | Phase 4 | 407 participants (Anticipated) | Interventional | 2022-06-25 | Recruiting | ||
| A Multi-Center, Randomized, Double-Blind Study of E3810 for Japanese Subjects With Functional Dyspepsia[NCT01089543] | Phase 2 | 338 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy as Rescue Treatment for Helicobacter Pylori Infection After Failure of Several Therapy[NCT02894268] | Phase 4 | 300 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | ||
| Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication[NCT02547038] | 352 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori[NCT01922765] | Phase 4 | 540 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| The Effect of Different Time Intervals on Rescue Treatment of Helicobacter Pylori Infection: a Prospective, Multicenter Observational Study[NCT05620589] | 626 participants (Anticipated) | Observational | 2022-11-11 | Not yet recruiting | |||
| The Effect of Different Time Intervals on Rescue Treatment of Helicobacter Pylori Infection: a Prospective, Multicenter Observational Study[NCT05620602] | 628 participants (Anticipated) | Observational | 2022-11-11 | Not yet recruiting | |||
| High Eradication Rate of Helicobacter Pylori Infection With Moxifloxacin-Based Triple Therapy in Comparison With Levofloxacin-Based Sequential Therapy: Randomized Controlled Trials[NCT05863858] | Phase 3 | 162 participants (Actual) | Interventional | 2020-06-01 | Completed | ||
| Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori[NCT05957432] | Phase 2 | 90 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT)[NCT00464308] | Phase 4 | 1,392 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| European Registry on the Management of Helicobacter Pylori Infection[NCT02328131] | 10,000 participants (Anticipated) | Observational | 2013-06-30 | Recruiting | |||
| Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy of Treatment of Helicobacter Pylori Infection in Korea[NCT02108184] | Phase 4 | 264 participants (Anticipated) | Interventional | 2014-02-28 | Recruiting | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| Comparative Recurrence Rate Investigation of Esomeprazole Versus Lansoprazole in Triple-Combination Therapy to Eradicate Helicobacter Pylori Infection Among Pediatrics: Multicentre, Randomized, and Controlled Trials[NCT05861687] | Phase 2/Phase 3 | 51 participants (Actual) | Interventional | 2021-08-01 | Completed | ||
| High Eradication Rates of Helicobacter Pylori With a New Sequential Treatment[NCT00132171] | Phase 3 | 1,000 participants | Interventional | 2001-01-31 | Completed | ||
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Stra[NCT02959255] | Phase 4 | 364 participants (Actual) | Interventional | 2017-01-30 | Completed | ||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Rifaximin Associated With Classic Triple Therapy (Inhibitor of Proton Pump, Amoxicillin and Clarithromycin) for the Eradication of Helicobacter Pylori Infection[NCT03124199] | Phase 3 | 40 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-controlled Trial[NCT00403364] | Phase 2/Phase 3 | 300 participants | Interventional | 2003-07-31 | Completed | ||
| Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori[NCT00149084] | Phase 3 | 296 participants | Interventional | 2003-04-30 | Recruiting | ||
| Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study[NCT04028466] | Phase 4 | 82 participants (Actual) | Interventional | 2019-05-26 | Terminated (stopped due to Budget for the study was withdrawn and discontinued) | ||
| Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication[NCT03650543] | Phase 4 | 133 participants (Actual) | Interventional | 2012-09-10 | Completed | ||
| Personalized Treatment for Refractory H Pylori Infection[NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The rate of complete dyspepsia symptom relief according to the Dyspepsia Symptom Questionnaire (DSQ) was defined as a score of 1 for all four major dyspeptic symptoms at week 8 and according to the diary defined as all four dyspepsia symptoms recorded absent during the 7 days prior to week 8. Values presented as percentage of participants. (NCT01089543)
Timeframe: Up to 8 Weeks (including 7 days prior)
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| DSQ (n= 76, n= 75, n= 74, n= 78) | Diary Recordings (n= 77, n= 76, n=74, n=80) | |
| Placebo | 17.9 | 17.5 |
| Rabeprazole 10 mg | 22.4 | 22.1 |
| Rabeprazole 20 mg | 29.3 | 28.9 |
| Rabeprazole 40 mg | 27.0 | 27.0 |
"The rate of satisfactory symptom relief according to the DSQ defined as scores of <= 2 for all four major dyspepsia symptoms at week 8 and the diary recordings defined as a frequency of <= 1 day for all four major dyspepsia symptoms during the 7 days before week 8. Lastly, treatment success according to the participants' impression questionnaire where participants answered yes or no when asked if given the choice, whether they would want to continue to take the study drug after clinical trial completion. Values presented as percentage of participants." (NCT01089543)
Timeframe: Up to 8 Weeks (including 7 days prior)
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| DSQ (n=76, n=75, n=74, n=78) | Diary Recordings (n=77, n=76, n=74, n=80) | Treatment Success (n=76, n=75, n=74, n=78) | |
| Placebo | 28.2 | 30.0 | 59.0 |
| Rabeprazole 10 mg | 42.1 | 37.7 | 72.4 |
| Rabeprazole 20 mg | 45.3 | 48.7 | 85.3 |
| Rabeprazole 40 mg | 39.2 | 39.2 | 64.9 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (Number of Participants With Complete Eradication of Helicobacter Pylori) (NCT02547038)
Timeframe: sixth week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 169 |
| (Panto+Amox+Clar+Metr)+(Panto+Amox) | 170 |
(NCT00464308)
Timeframe: 4 weeks
| Intervention | percent of participants (Mean) |
|---|---|
| Rabeprazole 20 mg/Day | 56.3 |
| Esomeprazole 40 mg/Day | 63.4 |
| Esomeprazole 20 mg/Day | 56.1 |
(NCT00464308)
Timeframe: 4 weeks
| Intervention | days (Median) |
|---|---|
| Rabeprazole 20 mg/Day | 9 |
| Esomeprazole 40 mg/Day | 11 |
| Esomeprazole 20 mg/Day | 13 |
(NCT00464308)
Timeframe: week 4 of treatment
| Intervention | days (Median) |
|---|---|
| Rabeprazole 20 mg/Day | 11 |
| Esomeprazole 40 mg/Day | 9 |
| Esomeprazole 20 mg/Day | 12 |
Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe. (NCT00464308)
Timeframe: 4 weeks
| Intervention | participants (Number) |
|---|---|
| Rabeprazole 20 mg/Day | 281 |
| Esomeprazole 40 mg/Day | 283 |
| Esomeprazole 20 mg/Day | 276 |
Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild) assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe. (NCT00464308)
Timeframe: 4 weeks
| Intervention | participants (Number) |
|---|---|
| Rabeprazole 20 mg/Day | 405 |
| Esomeprazole 40 mg/Day | 418 |
| Esomeprazole 20 mg/Day | 414 |
Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild)assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe. (NCT00464308)
Timeframe: 4 weeks
| Intervention | participants (Number) |
|---|---|
| Rabeprazole 20 mg/Day | 397 |
| Esomeprazole 40 mg/Day | 413 |
| Esomeprazole 20 mg/Day | 402 |
Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe. (NCT00464308)
Timeframe: week 4 of treatment
| Intervention | participants (Number) |
|---|---|
| Rabeprazole 20 mg/Day | 272 |
| Esomeprazole 40 mg/Day | 302 |
| Esomeprazole 20 mg/Day | 278 |
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
Percentage of patients that has comply with treatment, considered as intake of more than 90% of study drugs in patients who attended the post-treatment visit. (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 100 |
Percentage of Participants with H.Pylori Infection Eradication confirmed with urea breath test at least 4 weeks after the end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 61 |
Patients with side effects present during treatment and in the 4 weeks after end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| with diarrhea | with metallic taste | headache | nausea | abdominal pain | |
| Rifaximin | 13 | 9 | 5 | 5 | 1 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo+Tetra | 13 |
| Esomeprazole+Amox+Levo | 21 |
44 reviews available for rabeprazole and Infections, Helicobacter
| Article | Year |
|---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; | 2007 |
Network meta-analysis of different dosages of esomeprazole and rabeprazole for the treatment of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacte | 2023 |
Gastrointestinal: Rapid emergence of double-expressor lymphoma after Helicobacter pylori eradication therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Endoscopy, Digestive System; Follow-Up Studies; Gastric Mu | 2021 |
Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Contr | 2008 |
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Gastric Acid; Gastroesophagea | 2009 |
A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Chronic Disease; | 2011 |
Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esomep | 2012 |
Rabeprazole for the treatment of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Enzyme Inhibitors; Gastroesophageal Refl | 2012 |
Treatment and management of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agent | 2002 |
Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Helicobacter Infections; | 2003 |
Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; D | 2003 |
Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2004 |
Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastric Ac | 2004 |
[Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Female; | 2004 |
Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Gastroesop | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Benzimidazoles; Helicobacte | 2005 |
CYP2C19 genotype and the PPIs--focus on rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Aryl Hydrocar | 2005 |
[Establishment of 2nd line treatment regimen for H. pylori infection--future prospect for the application for national health insurance system in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Drug Therapy, Combination; Hel | 2005 |
[Recent topics on important drugs for H. pylori eradication: Rabeprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Benzi | 2005 |
[Second-line eradication therapy for H. pylori infection--PPI+AMPC+MNZ triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Drug Resistance, Bacterial; Dr | 2005 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydrox | 2005 |
[Investigation about 3rd line eradication of H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ampicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxy | 2005 |
The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2006 |
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Biotransf | 2007 |
Rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 1998 |
Review article: the pharmacology of rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimid | 1999 |
Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 1999 |
[Selection of antibiotics and planning of eradication for H. pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Administr | 2001 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
[Pariet in current patterns of eradication of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Administration Sche | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 2001 |
Rabeprazole: an update of its use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2001 |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2002 |
[Dual therapy for Helicobacter pylori resistance to anti microbial agents].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Clinical Trial | 2002 |
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug | 2002 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2002 |
[Second line treatment regimen of PPI + AMPC + MNZ for patients with clarithromycin-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Clinical Trial | 2002 |
[Minocycline-containing eradication therapy for patients with clarithromycin-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clarithromycin; Drug Administration Schedul | 2002 |
[Continuation of acid suppression therapy after H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Clinical Trials as Topic; Enzyme | 2002 |
[Proton pump inhibitors: Rabeprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Depression, Ch | 2002 |
[Cause and prevention of nocturnal gastric acid breakthrough].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rh | 2002 |
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2002 |
153 trials available for rabeprazole and Infections, Helicobacter
| Article | Year |
|---|---|
Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Hel | 2022 |
Metagenomic Changes of Gut Microbiota following Treatment of
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastrointestinal Microbiome; Helicobacter | 2022 |
A randomized controlled trial to compare Helicobacter pylori eradication rates between the empirical concomitant therapy and tailored therapy based on 23S rRNA point mutations.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2022 |
Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study.
Topics: Amoxicillin; Anti-Ulcer Agents; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Duodenal Ulcer; | 2022 |
Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Berberine; Bismuth; Clarithromycin; Drug Therapy, Combination; H | 2023 |
Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; China; Clarithromycin; Furazolidone; Helicobacter Infec | 2023 |
Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2023 |
Sequential Helicobacter pylori eradication therapy in Myanmar; a randomized clinical trial of efficacy and tolerability.
Topics: Amoxicillin; Clarithromycin; Drug Costs; Drug Therapy, Combination; Gastritis; Helicobacter Infectio | 2020 |
Comparative Study on Effect of Rabeprazole Versus Omeprazole in Acid-peptic Disorder with Helicobacter pylori Infection.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Cross-Sectional Studies; Drug Therapy, Combin | 2020 |
Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Bacterial; Drug Therapy, Com | 2020 |
Searching for an optimal therapy for H pylori eradication: High-dose proton-pump inhibitor dual therapy with amoxicillin vs. standard triple therapy for 14 days.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administrat | 2020 |
Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; China; Clarithromycin; Drug Resistance | 2020 |
Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Co | 2017 |
[[Clinical Relevance Helicobacter Pylori Genotypes in Patients with Chronic Pancreatitis and Concomitant Infections Helicobacter Pylori].]
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; He | 2016 |
Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Disk Diffusion Antimicrobial Tests; Drug | 2017 |
Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Asian People; Clarithromycin; Cytochrome P-450 CYP2C19; D | 2017 |
Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer.
Topics: Adenoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug | 2018 |
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter,
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Re | 2018 |
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter,
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Re | 2018 |
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter,
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Re | 2018 |
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter,
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Re | 2018 |
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter,
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Re | 2018 |
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter,
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Re | 2018 |
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter,
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Re | 2018 |
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter,
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Re | 2018 |
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter,
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Re | 2018 |
Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromy | 2018 |
Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dr | 2013 |
Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2013 |
Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan.
Topics: Double-Blind Method; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pyl | 2013 |
Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cyto | 2014 |
Comparison of Helicobacter pylori eradication rates of standard 14-day quadruple treatment and novel modified 10-day, 12-day and 14-day sequential treatments.
Topics: Adult; Anti-Infective Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Helic | 2014 |
A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; | 2013 |
Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 2014 |
Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Controlled Study in Japan.
Topics: Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Resi | 2015 |
Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy.
Topics: Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; | 2014 |
Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection.
Topics: Amoxicillin; Clavulanic Acid; Drug Combinations; Drug Resistance, Bacterial; Female; Helicobacter In | 2014 |
Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Drug Administration Schedule; Drug Therapy, Combin | 2014 |
New dual therapy for primary treatment of Helicobacter pylori infection: A prospective randomized study in Shanghai, China.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Drug Administration Schedule; Drug Therapy, Combin | 2014 |
Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; | 2015 |
Quadruple rescue therapy after first and second line failure for Helicobacter pylori treatment: comparison between two tetracycline-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Drug Resistance, Bacterial; Dru | 2014 |
Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combina | 2015 |
Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Ciprofloxacin; Clarithromycin; Drug Therapy, Combination; Fema | 2015 |
Different treatment choice for first-line treatment of Helicobacter pylori in an area with a high antibiotic resistance.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacteri | 2014 |
The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dental A | 2015 |
Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.
Topics: Aged; Anti-Bacterial Agents; Biopsy; Breath Tests; Clarithromycin; Drug Administration Schedule; Dru | 2015 |
Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Mal | 2015 |
Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial.
Topics: Acetylcysteine; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedu | 2016 |
Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
Topics: Aged; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacteria | 2015 |
Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; | 2015 |
A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Dexlansoprazole; Drug Resistance, Bacterial; Dru | 2016 |
Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospecti
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cytochrome P-450 CYP2C1 | 2016 |
[Effect of Helicobacter pylori eradication on patients with functional dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2008 |
Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; D | 2008 |
[Efficacy of 4 kinds of triple strategy for Helicobacter pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 2008 |
Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 2008 |
Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2009 |
Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2009 |
Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2009 |
The modified sequential treatment regimen containing levofloxacin for Helicobacter pylori eradication in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2009 |
Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2010 |
Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2010 |
The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2010 |
Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Ch
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2010 |
Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2011 |
A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Chronic Disease; | 2011 |
Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Ag | 2012 |
A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2012 |
Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2012 |
Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2012 |
"7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial".
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2011 |
Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzamides; Dyspepsia; Esop | 2012 |
Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti | 2012 |
Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2012 |
Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2012 |
A multicenter prospective observational study of triple therapy with rabeprazole, amoxicillin and metronidazole for Helicobacter pylori in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2012 |
Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents | 2013 |
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 2002 |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clar | 2002 |
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Respon | 2003 |
Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; | 2003 |
Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Cro | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Be | 2003 |
Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal A | 2003 |
High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Antacids; Anti-Ulcer Agents; Benz | 2003 |
[A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2003 |
Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Use of bovine lactoferrin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitric | 2003 |
Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylas | 2003 |
Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Ag | 2003 |
High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infect | 2004 |
Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2003 |
[Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hyd | 2004 |
[Comparative efficacy of proton pump inhibitors in children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; | 2003 |
Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benz | 2004 |
Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2004 |
Seven-day therapy for Helicobacter pylori in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles | 2004 |
Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Ant | 2004 |
Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Female; Gas | 2004 |
Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2004 |
Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Ba | 2004 |
Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2005 |
Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2005 |
One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2005 |
[Esomeprasol and rabeprasol effects on esophageal acidification in patients with gastroesophageal reflux disease, intensively metabolizing inhibitors of proton pump].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenoscopy; Esophagosc | 2005 |
Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Dis | 2005 |
[The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 2005 |
Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance o
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Benzimidazoles; Dose-Re | 2005 |
Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aminopyrine; Anti-Bacterial Agents; Anti-Infective Ag | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
[Five-day rabeprazole-based triple therapy for helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Clarithromycin; Drug Administrati | 2004 |
Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett | 2005 |
A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Antitrichomon | 2006 |
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Be | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2006 |
Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal A | 2006 |
Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; As | 2006 |
Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Bacterial Protei | 2006 |
Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aryl Hyd | 2006 |
A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cross-Over Studies; Drug Administ | 2006 |
[Helicobacter pylori erradication and its relation to antibiotic resistance and CYP2C19 status].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2007 |
Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2007 |
Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarb | 2007 |
Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug | 2007 |
Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: a multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2007 |
Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2008 |
Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Dr | 2007 |
Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2007 |
Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2007 |
Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2007 |
Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2007 |
Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug | 2007 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Co | 2008 |
[Clinical course of Helicobacter pylori associated chronic gastritis in post-eradicational period].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Di | 2007 |
Efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 1995 |
Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Dose-Respo | 1998 |
Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromy | 1998 |
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; D | 1999 |
Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2000 |
Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Anti-Ulcer A | 2000 |
Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidaz | 2000 |
Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2000 |
5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; D | 2000 |
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazo | 2001 |
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; | 2001 |
Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under | 2001 |
A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles | 2001 |
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2001 |
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2001 |
[Modern means of anti-Helicobacter therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2001 |
Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimid | 2001 |
Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Biopsy; | 2002 |
93 other studies available for rabeprazole and Infections, Helicobacter
| Article | Year |
|---|---|
The efficacy of culture-guided versus empirical therapy with high-dose proton pump inhibitor as third-line treatment of Helicobacter pylori infection: A real-world clinical experience.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Helic | 2022 |
Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2023 |
Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2023 |
Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2023 |
Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2023 |
[Dual therapy with rabeprazole and amoxicillin four times daily for 14 days for the first-line eradication of
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2019 |
Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2020 |
High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Heli | 2020 |
Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: A retrospective, real-life study.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; F | 2020 |
Efficacy of Sucralfate-Combined Quadruple Therapy on Gastric Mucosal Injury Induced by
Topics: Amoxicillin; Animals; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; | 2020 |
Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dr | 2020 |
Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Female; Follow-Up Studies; | 2021 |
Rabeprazole inhibits inflammatory reaction by inhibition of cell pyroptosis in gastric epithelial cells.
Topics: Adolescent; Anti-Inflammatory Agents; Anti-Ulcer Agents; Cell Line; Child; Child, Preschool; Epithel | 2021 |
Gastrointestinal: Idiopathic granulomatous gastritis observed by magnifying narrow-band imaging endoscopy.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diagnosis, Differential; Drug Therapy, Combinati | 2017 |
[The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroq | 2017 |
Successful eradication of Helicobacter pylori with a herbal medicine, goshuyuto (Wu Zhu Yu Tang), plus rabeprazole after failure of triplet therapy with vonoprazan: A report of three cases.
Topics: Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Helicobacter | 2018 |
Helicobacter pylori eradication may successfully treat primary cutaneous follicle center lymphoma.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Doxycycline; Female; Helicobacter Infec | 2018 |
Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: A pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Fe | 2019 |
Once-daily rabeprazole, levofloxacin, clarithromycin-MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study).
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female | 2019 |
Quadruple therapy for eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Chi-Square Distribution; Drug Therapy | 2013 |
Commentary: rabeprazole improves symptoms in patients with functional dyspepsia in Japan.
Topics: Dyspepsia; Female; Helicobacter Infections; Humans; Male; Proton Pump Inhibitors; Rabeprazole | 2013 |
Commentary: rabeprazole improves symptoms in patients with functional dyspepsia in Japan - author's reply.
Topics: Dyspepsia; Female; Helicobacter Infections; Humans; Male; Proton Pump Inhibitors; Rabeprazole | 2013 |
[Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Administr | 2014 |
Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; He | 2014 |
Tetracycline- and furazolidone-containing quadruple regimen as rescue treatment for Helicobacter pylori infection: a single center retrospective study.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; F | 2014 |
[Rationale for improved treatment of ulcerative disease complicated by chronic pyelonephritis].
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Diet; Female; Helicobacter In | 2013 |
The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Cohort Studies; Drug Ther | 2014 |
Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
Topics: Amoxicillin; Chronic Disease; Clarithromycin; Disease Eradication; Female; Gastritis; Helicobacter I | 2014 |
Helicobacter pylori treatment in children: defining a dose for rabeprazole as a part of a triple therapy regimen.
Topics: Adolescent; Amoxicillin; Area Under Curve; Body Weight; Child; Child, Preschool; Clarithromycin; Cli | 2015 |
Gastric inflammatory fibroid polyp morphologically changed by Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Endoscopy, Digestive System; Gastritis, Atrophic | 2015 |
Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Drug Administratio | 2015 |
High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Breath Tests; Drug Therapy, Combination; Female; Fluoroquinolone | 2015 |
Efficiency of Moxifloxacin in the Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Female; Fluoroquinolones; Helicobacter Infect | 2015 |
Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Drug Administration Schedule; D | 2015 |
Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Drug Administration Schedule; D | 2015 |
Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Drug Administration Schedule; D | 2015 |
Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Drug Administration Schedule; D | 2015 |
Letter: sitafloxacin for H. pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm.
Topics: Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Metronidazole; Rabeprazole | 2015 |
Letter: sitafloxacin for H. pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm - author's reply.
Topics: Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Metronidazole; Rabeprazole | 2015 |
Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; Breath Tests; Drug Administration Schedule | 2015 |
Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Cytoc | 2016 |
Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dr | 2016 |
The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Monitoring; Drug Therap | 2016 |
Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Resistance, Bacterial; Female; Fluoroquinolone | 2017 |
Two Cases of Chronic Gastritis with non-Helicobacter pylori Helicobacter Infection.
Topics: Amoxicillin; Clarithromycin; Endoscopy, Digestive System; Female; Gastric Mucosa; Gastritis; Helicob | 2016 |
Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Comb | 2017 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2008 |
[The first results of the program Effective Eradication in Novosibirsk].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cities; Helicobacter Infections; Helicob | 2008 |
In vitro antagonism of rabeprazole and metronidazole upon clinical isolates of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Synergism; Drug Th | 2009 |
Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Endoscopy; Esophagitis, Peptic; Female; Gastric Fundu | 2010 |
How to manage Helicobacter pylori after sequential therapy failure?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Child; Cli | 2010 |
Ten-day sequential therapy as first-line treatment for Helicobacter pylori infection in Korea: a retrospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithro | 2010 |
Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithr | 2010 |
[A case of mucosa-associated lymphoid tissue lymphoma with penicillin allergy successfully treated with levofloxacin, minomycin and rabeprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Drug Hypersensitivity; Female; Helicobacter Infecti | 2010 |
Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Aryl Hydrocarb | 2011 |
Regression of multiple duodenal hyperplastic polyps following Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 2011 |
Gastric wash-based molecular testing for antibiotic resistance in Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2011 |
Successful management of cap polyposis with eradication of Helicobacter pylori relapsing 15 years after remission on steroid therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2012 |
High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Drug Therapy, Combination; Follow-Up Studies; Heli | 2012 |
Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2012 |
[Seven-day antihelicobacter therapy of duodenal ulcer associated with Helicobacter pylori and prospects for treating patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Ad | 2002 |
[Pariet in eradication therapy plans].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; D | 2002 |
Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2002 |
A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2002 |
Rabeprazole treatment attenuated Helicobacter pylori-associated gastric mucosal lesion formation in Mongolian gerbils.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analysis of Variance; Animals; Anti-Ulcer Agents; Benzimida | 2003 |
A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer | 2003 |
Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Academic Medical Centers; Adult; Aryl Hydrocarbon Hydroxyla | 2003 |
[Medico-economic efficacy of eradication schemes in helicobacter infections in patients with duodenal ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Benzimidazoles; Cost of Illne | 2003 |
Lactoferrin: milking ulcers?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cattle; Clarithromycin; Drug Thera | 2003 |
Retreatment of H. pylori with dual therapy using high doses of rabeprazole or lansoprazole can be effective.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2003 |
Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Aryl Hydrocarbon Hydrox | 2004 |
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Benz | 2004 |
Results of triple eradication therapy in Japanese children: a retrospective multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; | 2004 |
Amoxicillin resistance in Helicobacter pylori: studies from Tokyo, Japan from 1985 to 2003.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidaz | 2005 |
[Is anti-helicobacter therapy a rational approach in treatment of erosive and ulcerous lesions of the gastroduodenal mucosa in patients with inflamatory bowel diseases?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2005 |
New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; | 2005 |
A new-generation H2 receptor antagonist: quicker and stronger acid inhibition than proton pump inhibitors in the clinical setting?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Benzimidazoles; Gastric Acid; Gastric Acidity D | 2005 |
Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Benz | 2006 |
Efficacy of Helicobacter pylori eradication on the chronic mucosal inflammation of the remnant stomach after distal gastrectomy for early gastric cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer | 2005 |
"Best practice' for Helicobacter pylori eradication in the primary care setting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2006 |
Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2006 |
Effects of rabeprazole or famotidine during cardiac surgery on perioperative gastric and esophageal pH readings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2006 |
Pharmacodynamic studies on PPIs: look carefully at the country of origin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; As | 2006 |
Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cohort Studies; Enzyme Inhibitors; Female; Gastroesophageal | 2006 |
[Results of the treatment of duodenal ulcer associated with Helicobacter pylori and combined with gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 2005 |
[Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Cost-Benefit Analysis; Drug Th | 2007 |
14-day quadruple therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Ag | 2006 |
Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon | 2008 |
Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon | 2008 |
Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon | 2008 |
Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon | 2008 |
Helicobacter pylori infection influences nocturnal gastric acid breakthrough.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; | 2000 |
Effect of amoxicillin, clarithromycin, and rabeprazole, a new proton pump inhibitor, in eradication therapy for relapsing peptic ulcer diseases with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2000 |
4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles | 2001 |
Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cell Division; Clarithromycin; Dose-Respons | 2001 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alleles; Amoxicillin; Aryl Hydrocarbon Hydroxy | 2001 |
Duodenal mucosa-associated lymphoid tissue lymphoma treated by eradication of Helicobacter pylori: report of 2 cases including EUS findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Benzimidazoles; Biopsy, Needle; Clarithr | 2001 |
Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2002 |
Helicobacter pylori eradication: do we have another ace up our sleeve?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Anti-Infective Agents; Be | 2001 |
Primary hyperparathyroidism with duodenal ulcer and H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Aged; Anti-Ulcer Agents; Benzimidazoles; Duodenal | 2002 |